Portfolio | Ansun生物制药成功完成A轮8500万美金融资

美国加州圣地亚哥，2018年5月14日——Ansun制药公司宣布完成8500万美元A轮融资。Ansun是一家领先的生物技术公司，致力于开发新型广谱抗病毒生物药剂以对抗严重的病毒性呼吸道感染。

本轮融资由国药资本和礼来亚洲基金领投。参与本轮投资的其他新投资者包括济峰资本、元明资本、经纬中国、本草资本、海松资本、弘励创投和中楷投资。

Ansun计划用本轮募集的资金来支持其实验性抗病毒药物DAS181的三期临床试验。 FDA已授予DAS181快速通道和突破性治疗资格认定。Ansun目前正在计划进行针对感染了副流感病毒的住院免疫减退患者的三期临床试验。

DAS181有望成为用于治疗呼吸道病毒感染的first-in-class生物新药，其中包括流感、副流感、和偏肺病毒等。 DAS181是一种重组唾液酸酶蛋白，可以切割位于人体呼吸道上皮细胞表面的病毒受体唾液酸。DAS181疗法可以阻止病毒进入呼吸道上皮细胞，从而防止病毒感染和传播。 DAS181是一种宿主靶向治疗药物，它已经被证明对所有以唾液酸为受体的病毒株和病毒亚型具有抗病毒活性。这些病毒中包括对其它药物产生耐药性的流感病毒株，和包括H7N9、H5N1和H1N1以及许多其它病毒在内的大流行病毒株。这一广泛的抗病毒活性为Ansun公司提供了独一无二的开发和商业化DAS181的机会，以治疗许多不同类型的病毒感染。迄今为止，Ansun公司已开发用于治疗住院流感和住院副流感的剂型——这两个疾病领域每年造成全世界数十万人死亡，医疗需求尚未得到满足。

Ansun还宣布了董事会的人员变更。来自国药资本的杨晓明博士和礼来亚洲基金的施毅博士，以及Donald Payne先生和Michael Chao博士将共同加入董事会。他们会与现任董事会成员Allen Chao博士，唐南珊博士和Michael Chang博士一起共事。

“我们很高兴能够从全球几家最受瞩目的生物技术投资机构获得强有力的财务支持，”Ausun公司代理首席执行官唐南珊博士说到，“和这些财务支持同样甚至更重要的是，我们的董事会能够获得新董事会成员的宝贵知识和经验。”

杨晓明博士表示：“全球因流感和副流感等非常危险的呼吸道传染病肆虐，而面临日益严峻的威胁。我们很乐意在这一大背景下，领导本轮投资。我们期待与公司，董事会及其管理层紧密合作，迅速推进DAS181的研发，让更多患者能尽快受益。”

关于Ansun生物制药

 Ansun生物制药是一家位于美国加利福尼亚州圣地亚哥的临床阶段生物制药公司，致力于开发针对呼吸道病毒的独特宿主靶向抗病毒疗法。目前Ansun正在与FDA合作，计划和实施DAS181的三期临床试验，用于治疗住院和免疫功能减退患者的副流感感染。除突破性资格认定外，DAS181还获得了美国FDA对此适应症的快速通道指定。最近，该公司已经观察到DAS181基于相同宿主靶向的抗病毒机制、针对其他重要呼吸道病原体的活性。欲了解更多信息，请访问www.ansunbiopharma.com或在www.clinicaltrials.gov网站上使用标识号NCT01644877查询。

联系方式 

Ansun BioPharma, Inc.

Public and investor relations:

Mike Havluciyan, 858-452-2631 ext. 186

附英文新闻：

Ansun BioPharma secures $85 million in Series A Financing

SAN DIEGO, May 14, 2018 /PRNewswire/ -- Ansun BioPharma, Inc., a leading biotechnology company focused on the development of novel broad spectrum anti-viral biologic therapeutics to combat severe viral respiratory tract infections, today announced the completion of an $85 million Series A financing round.

The round was led by Sinopharm Healthcare Fund and Lilly Asia Ventures.  Additional new investors participating in this round included Lyfe Capital, Yuanming Capital, Matrix Partners China, 3e Bioventures Capital, Oceanpine Capital, VI Ventures, and Joincap Investment. 

Ansun plans to use the proceeds from the Series A to fund a Phase 3 clinical trial of its experimental anti-viral medication, DAS181.  The FDA has granted both Fast Track status and Breakthrough therapy designation to DAS181, and Ansun is currently in the planning stage of a Phase 3 trial to treat hospitalized, immunocompromised subjects infected with parainfluenza virus. 

DAS181 is a potentially first-in-class therapeutic that can be used to treat respiratory viral infections, including, but not limited to influenza, parainfluenza, and metapneumovirus. DAS181 is a recombinant sialidase protein that can cleave sialic acid, the virus receptors located on the surface of epithelial cells aligning the human respiratory track. Treatment with DAS181 can block virus entry into respiratory epithelial cells, thus preventing viral infection and spreading. DAS181 is a host-directed therapeutic that has demonstrated anti-viral activity against all strains and subtypes of viruses that utilize this receptor, including influenza strains that have developed resistance to other drugs and pandemic strains, such as H7N9, H5N1, and H1N1 and many others. This broad activity provides Ansun a unique opportunity to develop and commercialize DAS181 for treatment of many different viral infections. To date, Ansun has created formulations of this drug which it is developing to treat both hospitalized influenza and hospitalized parainfluenza , both of which are areas of unmet medical need that cause hundreds of thousands of deaths each year around the world.

Ansun has also announced changes to its Board. Dr. Xiaoming Yang from Sinopharm Capital and Dr. Yi Shi from Lilly Asia Ventures will be joining the Board. Mr. Donald Payne and Dr. Michael Chaowill also be joining the Board. They will serve alongside existing Board members Dr. Allen Chao, Dr. Nancy Chang, and Dr. Michael Chang. 

"We are delighted to secure this strong financial support from some of the most highly regarded biotechnology investment groups in the world," said Dr. Nancy Chang, the interim CEO of Ansun.  "And just as important, if not more important, than their financial support is the depth of knowledge and experience our Board will gain with our new Board members," explained Dr. Chang.

"We are very pleased to be leading this round in Ansun against a backdrop of increasing threat worldwide from very dangerous respiratory infectious diseases like influenza and parainfluenza,"  said Dr. Yang. "We look forward to working closely with the Company, its Board of Directors and its management to rapidly progress the development of DAS181 so that it can benefit as many people as quickly as possible," he added. 

About Ansun BioPharma

Ansun BioPharma is a clinical stage biopharmaceutical company based in San Diego, California focused on the development of unique host-directed anti-viral therapies for respiratory viruses.  Ansun is currently working with FDA to plan and implement a Phase 3 clinical trial of DAS181 for the treatment of PIV infection in hospitalized and immunocompromised patients. In addition to Breakthrough Designation, DAS181 has also received Fast Track designation by the U.S. FDA for this indication. Recently the company has observed activity of DAS181 against other important respiratory pathogens based on the same host-directed anti-viral mechanism. For more information, please visit www.ansunbiopharma.com or www.clinicaltrials.gov using the identifier NCT01644877.

SOURCE Ansun BioPharma

Related Links

http://www.ansunbiopharma.com

近期文章

Portfolio公司新闻

行业趋势

原创

欢迎关注：